

At page 18, line 4, please replace "calcein-AM" with --CALCEIN-AM--.

At page 21, line 20, please replace "AquaSil" with --AQUASIL--.

At page 28, lines 15 and 23, please replace "Fluo-3" with --FLUO-3--.

### REMARKS

It is respectfully requested that the above amendments and following remarks be considered. Claims 16, 18, 22 and 23-26 are currently pending in this application. Claims 16 and 22 have been amended.

#### Amendments

Claim 16 has been amended to delete the term "is capable of flowing in the microfluidic device to" and to amend the claim to positively state that the method comprises applying into the microfluidic device at least one cell which flows into a first inlet flow path.

Claim 22 has been amended to change the dependency to claim 16.

The specification has been amended in several locations to capitalize trademarks.

No new matter is added by these amendments.

#### Formalities

The disclosure is objected to because of the use of the following abbreviations in the specification: MSE; SNAFL; SNARF; HSG-IMT VAMP; Pt; COPI.